<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361136</url>
  </required_header>
  <id_info>
    <org_study_id>LP0133-1408</org_study_id>
    <secondary_id>2019-000705-67</secondary_id>
    <nct_id>NCT04361136</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream</brief_title>
  <official_title>A Phase 1 Clinical Trial to Evaluate the Phototoxic Potential of Delgocitinib Cream After Single Topical Occlusive Application on Healthy Skin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, randomised, vehicle-controlled, double-blind, within-subject
      comparison phase 1 clinical trial. The trial is designed to find out if delgocitinib cream
      can cause skin irritation after light exposure in people with healthy skin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 4, 2020</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects will receive all treatments with treatments randomised over test fields.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive skin reaction at 24 hours or 48 hours after irradiation</measure>
    <time_frame>Up to 48 hours after irradiation</time_frame>
    <description>A reaction is considered positive if the skin reaction score for the irradiated test field is at least 1 point higher than both the non-irradiated test field exposed to the same strength of IMP, and the irradiated control field.
The grading for the skin reaction score will be performed according to the following 5-point scale:
0 No reaction
1 Erythema
2 Erythema with dermal infiltrate
3 Erythema with papulovesicles
4 Erythema with blisters, erosions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive skin reaction at 24 hours after irradiation</measure>
    <time_frame>24 hours after irradiation</time_frame>
    <description>A reaction is considered positive if the skin reaction score for the irradiated test field is at least 1 point higher than both the non-irradiated test field exposed to the same strength of IMP, and the irradiated control field.
The grading for the skin reaction score will be performed according to the following 5-point scale:
0 No reaction
1 Erythema
2 Erythema with dermal infiltrate
3 Erythema with papulovesicles
4 Erythema with blisters, erosions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive skin reaction at 48 hours after irradiation</measure>
    <time_frame>48 hours after irradiation</time_frame>
    <description>A reaction is considered positive if the skin reaction score for the irradiated test field is at least 1 point higher than both the non-irradiated test field exposed to the same strength of IMP, and the irradiated control field.
The grading for the skin reaction score will be performed according to the following 5-point scale:
0 No reaction
1 Erythema
2 Erythema with dermal infiltrate
3 Erythema with papulovesicles
4 Erythema with blisters, erosions</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of treatment-emergent adverse events from baseline to Day 4</measure>
    <time_frame>From time of first investigational medicinal product application (Day 1) until Day 4</time_frame>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Delgocitinib cream 1 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream 3 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream 8 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream 20 mg/g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delgocitinib cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single topical occlusive administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delgocitinib cream</intervention_name>
    <description>Cream for topical application</description>
    <arm_group_label>Delgocitinib cream 1 mg/g</arm_group_label>
    <arm_group_label>Delgocitinib cream 20 mg/g</arm_group_label>
    <arm_group_label>Delgocitinib cream 3 mg/g</arm_group_label>
    <arm_group_label>Delgocitinib cream 8 mg/g</arm_group_label>
    <other_name>LEO 124249 cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delgocitinib cream vehicle</intervention_name>
    <description>The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.</description>
    <arm_group_label>Delgocitinib cream vehicle</arm_group_label>
    <other_name>LEO 124249 cream vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Healthy subjects aged 18-64 years (inclusive).

          -  Fitzpatrick skin type of I, II, or III.

        Key Exclusion Criteria:

          -  Atopic dermatitis, eczema, psoriasis, acne, dermatitis solaris or suntan that could
             interfere with the test field evaluation, hyperpigmentation, multiple naevi, tattoos,
             blemishes or dense body hair in the range of the test fields.

          -  Any history of or presence of cancerous or precancerous skin lesions.

          -  Any other skin disease or other visible skin condition noted on physical examination
             which in the investigator's opinion might interfere with the evaluation of the test
             field reaction.

          -  Known disease that can be induced by ultraviolet (UV) light.

          -  Use of any topical or systemic medication which could interfere with the trial
             objective within 2 weeks before randomisation until end of trial.

          -  Use of drugs which might cause photobiologic or phototoxic reactions within 4 weeks
             before randomisation until end of trial.

          -  Foreseeable intensive UV light exposure (solar or artificial) to test fields within 4
             weeks before randomisation until end of trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bioskin Research Center Dermatology</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD can be made available to researchers in a closed environment for a specified period of time.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data is available to request after results of the trial are available on leopharmatrials.com</ipd_time_frame>
    <ipd_access_criteria>Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.</ipd_access_criteria>
    <ipd_url>http://leopharmatrials.com/for-professionals</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

